Developer docs
API playgroundTry for free, no card

Search company profiles

Molefy pharma

Full company profile

uuid005d2dr

Namestring
Molefy pharma
Legal namestring
Molefy Pharma SL
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Molefy Pharma is a clinical-stage Spanish biotechnology company founded in 2024 as a spin-off of ARQUIMEA (majority investor) and CSIC (Consejo Superior de Investigaciones Científicas), developing small-molecule therapeutics that target TDP-43 proteinopathy in neurodegenerative diseases. Its lead candidate AP-2 is a CK1δ kinase inhibitor designed to restore TDP-43 cellular homeostasis, with the goal of halting and reversing disease progression in Amyotrophic Lateral Sclerosis (ALS). AP-2 received Orphan Drug Designation from the European Medicines Agency in October 2025 and was authorized by the Spanish Agency of Medicines (AEMPS) to begin Phase I clinical trials in approximately 70 healthy volunteers at Hospital Universitario de La Princesa (Madrid) in April 2026, with a Phase Ib in ~24-28 ALS patients planned from 2027 and a multicenter Phase II from 2028. A second preclinical candidate, AP-3, inhibits the TTBK1 enzyme for frontotemporal dementia and is supported by the Alzheimer's Drug Discovery Foundation.

The company operates a research-driven, grant- and equity-funded business model with no commercial revenue. Capital sources include ARQUIMEA's majority equity stake, a $1 million non-refundable grant from the ALS Association (October 2025), preclinical funding from ADDF, and a planned Phase II investment round targeting institutional investors, VC funds, and strategic partners. The pipeline is built on foundational CSIC patents (CK-1δ filed 2013; TTBK1 filed 2021) licensed to Molefy Pharma at founding, with efficacy demonstrated in patient-derived cellular models and rodent and minipig animal studies. The ~8-person core team is led by CEO Alfonso de Egaña with scientific co-founders Ana Martínez PhD and Carmen Gil PhD (CIB-CSIC researchers), and a Scientific Advisory Board that includes Don W. Cleveland (UC San Diego). The company is headquartered in San Cristóbal de La Laguna, Tenerife, with clinical operations in Madrid.

Short descriptiontext

Molefy Pharma is a clinical-stage Spanish biotech developing small-molecule therapeutics that target TDP-43 proteinopathy in neurodegenerative diseases. Its lead candidate AP-2 is in Phase I trials for ALS, and AP-3 is in preclinical development for frontotemporal dementia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Cristóbal De La Laguna, Spain
HQ citystring
San Cristóbal De La Laguna
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, ALS treatment development, small molecule drugs, frontotemporal dementia therapy, TDP-43 proteinopathy treatment
Industry2 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals / Neurology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical / Biopharmaceutical product revenues
TypeOne Time License
Description

Pre-revenue. The company is developing AP-2 as a disease-modifying therapy for ALS. Upon successful clinical development and regulatory approval, the company aims to commercialize the therapy and generate product revenues. The company is also developing AP-3 for frontotemporal dementia.

molefypharma.com
2Non-dilutive funding (grants)
TypeLicensing Royalties
Description

Molefy Pharma pursues non-dilutive funding from public and private sources including the ALS Association ($1 million awarded in 2025) and the Alzheimer's Drug Discovery Foundation (funding AP-3 preclinical work). These grants support clinical trial and preclinical development without diluting equity.

molefypharma.com
3Equity investment rounds
TypeAffiliate Referral
Description

The company is currently in an active fundraising phase and plans to launch a Phase II investment round targeting institutional investors, venture capital funds, and strategic partners. ARQUIMEA is the majority investor.

molefypharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Molefy Pharma is a clinical-stage biotech company developing small-molecule therapeutics for neurodegenerative diseases. Its lead candidate AP-2, a CK1δ kinase inhibitor that restores TDP-43 protein homeostasis, is in Phase I clinical trials for Amyotrophic Lateral Sclerosis (ALS). Its second candidate AP-3, a TTBK1 inhibitor, is in preclinical development for frontotemporal dementia (FTD). Both are based on foundational patents licensed from CSIC and validated in patient-derived cellular and animal models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I clinical trial authorized by AEMPS (April 2026) with ~70 healthy volunteers to assess safety; Phase Ib planned with ~28 ALS patients from 2027; Phase II from 2028
+2 more records
Product overview1 text field

Molefy Pharma is a biotech company with a focused pipeline of two therapeutic candidates for neurodegenerative diseases. The lead product AP-2 is a small molecule in Phase I clinical development for ALS, targeting TDP-43 proteinopathy. The secondary candidate AP-3 is in preclinical development for frontotemporal dementia. The company's scientific approach combines molecular biology research from CSIC with industrial development capabilities from ARQUIMEA.

Product and service2 records
1AP-2
CategorySmall molecule therapeutic for ALS
Description

Small molecule therapeutic candidate designed to restore cellular balance by regulating TDP-43 protein homeostasis via CK1δ kinase inhibition. AP-2 targets the TDP-43 proteinopathy found in over 97% of ALS patients, with potential to not only alleviate symptoms but reverse cellular dysfunction. Demonstrated reversal of cognitive deficits in ALS mouse models and favorable safety in rodent and minipig studies under GMP conditions. Phase I clinical trial for Amyotrophic Lateral Sclerosis (ALS).

2AP-3
CategorySmall molecule therapeutic for frontotemporal dementia
Description

Preclinical therapeutic candidate for frontotemporal dementia (FTD). AP-3 is a compound that inhibits the TTBK1 enzyme, which plays a key role in TDP-43 protein alteration and pathology in frontotemporal dementia. Demonstrated significant memory improvement, neuronal preservation, and favorable safety profile in animal models, with strong brain penetration and high selectivity.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Hospital Universitario de La Princesa (Madrid)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-01
Description

Phase I clinical trial site for AP-2, authorized by AEMPS. The Clinical Trials Unit at Hospital Universitario de La Princesa (Madrid) will evaluate AP-2 safety in approximately 70 healthy volunteers beginning April 2026. Subsequent Phase Ib will include approximately 28 ALS patients.

molefypharma.com
2ENCALS (European Network to Cure ALS)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

ENCALS is Europe's foremost collaborative platform for ALS research, gathering leading ALS centers, clinicians, and scientists to foster data harmonization, translational science, and collaborative clinical development. Molefy Pharma presented three scientific papers at ENCALS 2025 in Turin, reinforcing strategic European partnerships and scientific credibility.

molefypharma.com
3CSIC (Consejo Superior de Investigaciones Científicas)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

CSIC is the principal public research institution in Spain and a leading European research body. Provides scientific excellence, cutting-edge molecular biology research, and foundational patents (CK-1º and TTBK1) that underpin Molefy Pharma's therapeutic candidates. Researchers Ana Martínez and Carmen Gil from CIB-CSIC are co-founders. The license transfer from CSIC to Molefy Pharma formally launched the company.

molefypharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Clinical-stage biotech whose pipeline (PRX012, tau programs) targets proteinopathies including TDP-43-related neurodegeneration. Directly comparable mechanism focus on misfolded protein clearance in neurodegenerative diseases.

TypeDirect peer
Description

Clinical-stage biotech advancing small-molecule ALS therapeutics (reldesemtiv). Directly comparable late-stage clinical ALS competitor developing mechanistically distinct muscle/neuromuscular candidates.

TypeBroad incumbent
Description

Large incumbent in neurodegenerative disease drug development (Spinraza, Tofersen for SOD1-ALS, Aduhelm). Owns the most relevant ALS franchise and a broad CNS pipeline that competes for the same regulatory and commercial slots.

TypeDirect peer
Description

Clinical-stage biotech developing small-molecule therapies for ALS (AMX0035/Relyvrio). Most directly comparable peer as a small-molecule disease-modifying ALS developer with similar regulatory and clinical-stage profile.

TypeEmerging player
Description

Early-stage biotech developing antisense oligonucleotides targeting TDP-43 and other ALS mechanisms. Highly comparable focus on TDP-43 proteinopathy from a different (ASO) modality angle.

TypeEmerging player
Description

Clinical-stage small-molecule developer focused on ion channel and kinase targets for neuroscience indications including ALS. Comparable as a small-cap small-molecule neuroscience biotech.

TypeBroad incumbent
Description

Large antisense oligonucleotide platform leader with multiple ALS programs (partnering with Biogen on Tofersen, internal programs). Sets the innovation benchmark in TDP-43/SOD1-ALS therapeutic development.

8Ankarpharma SL
TypeOthers
Description

Earlier CSIC spin-off that held the CK-1δ patent transferred to Molefy Pharma at founding (2014). Direct lineage comparable as a Spanish neurodegenerative spin-off from the same research group.

TypeEmerging player
Description

Clinical-stage biotech developing CNM-Au8, a gold nanocatalyst for ALS and other neurodegenerative diseases. Comparable emerging clinical-stage ALS therapeutics competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molefy pharma

Biopharmaceuticals / Neurology Therapeuticsmolefypharma.com

Molefy Pharma is a clinical-stage Spanish biotech developing small-molecule therapeutics that target TDP-43 proteinopathy in neurodegenerative diseases. Its lead candidate AP-2 is in Phase I trials for ALS, and AP-3 is in preclinical development for frontotemporal dementia.

What Molefy pharma does

Molefy Pharma is a clinical-stage Spanish biotechnology company founded in 2024 as a spin-off of ARQUIMEA (majority investor) and CSIC (Consejo Superior de Investigaciones Científicas), developing small-molecule therapeutics that target TDP-43 proteinopathy in neurodegenerative diseases. Its lead candidate AP-2 is a CK1δ kinase inhibitor designed to restore TDP-43 cellular homeostasis, with the goal of halting and reversing disease progression in Amyotrophic Lateral Sclerosis (ALS). AP-2 received Orphan Drug Designation from the European Medicines Agency in October 2025 and was authorized by the Spanish Agency of Medicines (AEMPS) to begin Phase I clinical trials in approximately 70 healthy volunteers at Hospital Universitario de La Princesa (Madrid) in April 2026, with a Phase Ib in ~24-28 ALS patients planned from 2027 and a multicenter Phase II from 2028. A second preclinical candidate, AP-3, inhibits the TTBK1 enzyme for frontotemporal dementia and is supported by the Alzheimer's Drug Discovery Foundation.

The company operates a research-driven, grant- and equity-funded business model with no commercial revenue. Capital sources include ARQUIMEA's majority equity stake, a $1 million non-refundable grant from the ALS Association (October 2025), preclinical funding from ADDF, and a planned Phase II investment round targeting institutional investors, VC funds, and strategic partners. The pipeline is built on foundational CSIC patents (CK-1δ filed 2013; TTBK1 filed 2021) licensed to Molefy Pharma at founding, with efficacy demonstrated in patient-derived cellular models and rodent and minipig animal studies. The ~8-person core team is led by CEO Alfonso de Egaña with scientific co-founders Ana Martínez PhD and Carmen Gil PhD (CIB-CSIC researchers), and a Scientific Advisory Board that includes Don W. Cleveland (UC San Diego). The company is headquartered in San Cristóbal de La Laguna, Tenerife, with clinical operations in Madrid.

Molefy pharma firmographics

Firmographics
Name
Molefy pharma
Legal name
Molefy Pharma SL
Website
https://molefypharma.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Molefy Pharma is a clinical-stage Spanish biotech developing small-molecule therapeutics that target TDP-43 proteinopathy in neurodegenerative diseases. Its lead candidate AP-2 is in Phase I trials for ALS, and AP-3 is in preclinical development for frontotemporal dementia.
Ownership category
akta.pro rank

Molefy pharma industry classification

Industry
Product category
Biopharmaceuticals / Neurology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • ALS treatment development
  • Small molecule drugs
  • Frontotemporal dementia therapy
  • TDP-43 proteinopathy treatment

Where Molefy pharma is headquartered

Location

Headquarters

HQ city
San Cristóbal De La Laguna
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Molefy pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical / Biopharmaceutical product revenues: Pre-revenue. The company is developing AP-2 as a disease-modifying therapy for ALS. Upon successful clinical development and regulatory approval, the company aims to commercialize the therapy and generate product revenues. The company is also developing AP-3 for frontotemporal dementia.
  2. Non-dilutive funding (grants): Molefy Pharma pursues non-dilutive funding from public and private sources including the ALS Association ($1 million awarded in 2025) and the Alzheimer's Drug Discovery Foundation (funding AP-3 preclinical work). These grants support clinical trial and preclinical development without diluting equity.
  3. Equity investment rounds: The company is currently in an active fundraising phase and plans to launch a Phase II investment round targeting institutional investors, venture capital funds, and strategic partners. ARQUIMEA is the majority investor.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Molefy pharma product offering

Product offering

Core offering

Molefy Pharma is a clinical-stage biotech company developing small-molecule therapeutics for neurodegenerative diseases. Its lead candidate AP-2, a CK1δ kinase inhibitor that restores TDP-43 protein homeostasis, is in Phase I clinical trials for Amyotrophic Lateral Sclerosis (ALS). Its second candidate AP-3, a TTBK1 inhibitor, is in preclinical development for frontotemporal dementia (FTD). Both are based on foundational patents licensed from CSIC and validated in patient-derived cellular and animal models.

Product overview

Molefy Pharma is a biotech company with a focused pipeline of two therapeutic candidates for neurodegenerative diseases. The lead product AP-2 is a small molecule in Phase I clinical development for ALS, targeting TDP-43 proteinopathy. The secondary candidate AP-3 is in preclinical development for frontotemporal dementia. The company's scientific approach combines molecular biology research from CSIC with industrial development capabilities from ARQUIMEA.

Differentiator

Problem solved

Functional benefit

Products and services

  • AP-2 Small molecule therapeutic candidate designed to restore cellular balance by regulating TDP-43 protein homeostasis via CK1δ kinase inhibition. AP-2 targets the TDP-43 proteinopathy found in over 97% of ALS patients, with potential to not only alleviate symptoms but reverse cellular dysfunction. Demonstrated reversal of cognitive deficits in ALS mouse models and favorable safety in rodent and minipig studies under GMP conditions. Phase I clinical trial for Amyotrophic Lateral Sclerosis (ALS).
  • AP-3 Preclinical therapeutic candidate for frontotemporal dementia (FTD). AP-3 is a compound that inhibits the TTBK1 enzyme, which plays a key role in TDP-43 protein alteration and pathology in frontotemporal dementia. Demonstrated significant memory improvement, neuronal preservation, and favorable safety profile in animal models, with strong brain penetration and high selectivity.

Quantifiable outcome

  • Phase I clinical trial authorized by AEMPS (April 2026) with ~70 healthy volunteers to assess safety; Phase Ib planned with ~28 ALS patients from 2027; Phase II from 2028
  • +2 more outcomes

Companies that use Molefy pharma

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Molefy pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Molefy pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • Hospital Universitario de La Princesa (Madrid)coreImplementation/ SI/ Consulting Partner · 1 January 2026Phase I clinical trial site for AP-2, authorized by AEMPS. The Clinical Trials Unit at Hospital Universitario de La Princesa (Madrid) will evaluate AP-2 safety in approximately 70 healthy volunteers beginning April 2026. Subsequent Phase Ib will include approximately 28 ALS patients.
  • ENCALS (European Network to Cure ALS)majorStrategic or Co-development Partner · 1 January 2025ENCALS is Europe's foremost collaborative platform for ALS research, gathering leading ALS centers, clinicians, and scientists to foster data harmonization, translational science, and collaborative clinical development. Molefy Pharma presented three scientific papers at ENCALS 2025 in Turin, reinforcing strategic European partnerships and scientific credibility.
  • CSIC (Consejo Superior de Investigaciones Científicas)coreStrategic or Co-development Partner · 1 January 2024CSIC is the principal public research institution in Spain and a leading European research body. Provides scientific excellence, cutting-edge molecular biology research, and foundational patents (CK-1º and TTBK1) that underpin Molefy Pharma's therapeutic candidates. Researchers Ana Martínez and Carmen Gil from CIB-CSIC are co-founders. The license transfer from CSIC to Molefy Pharma formally launched the company.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Molefy pharma competitors and assessment

Company assessment

Direct peers

  • Prothena: Clinical-stage biotech whose pipeline (PRX012, tau programs) targets proteinopathies including TDP-43-related neurodegeneration. Directly comparable mechanism focus on misfolded protein clearance in neurodegenerative diseases.
  • Cytokinetics: Clinical-stage biotech advancing small-molecule ALS therapeutics (reldesemtiv). Directly comparable late-stage clinical ALS competitor developing mechanistically distinct muscle/neuromuscular candidates.
  • Amylyx Pharmaceuticals: Clinical-stage biotech developing small-molecule therapies for ALS (AMX0035/Relyvrio). Most directly comparable peer as a small-molecule disease-modifying ALS developer with similar regulatory and clinical-stage profile.

Broad incumbents

  • Biogen: Large incumbent in neurodegenerative disease drug development (Spinraza, Tofersen for SOD1-ALS, Aduhelm). Owns the most relevant ALS franchise and a broad CNS pipeline that competes for the same regulatory and commercial slots.
  • Ionis Pharmaceuticals: Large antisense oligonucleotide platform leader with multiple ALS programs (partnering with Biogen on Tofersen, internal programs). Sets the innovation benchmark in TDP-43/SOD1-ALS therapeutic development.

Emerging players

  • QurAlis Corporation: Early-stage biotech developing antisense oligonucleotides targeting TDP-43 and other ALS mechanisms. Highly comparable focus on TDP-43 proteinopathy from a different (ASO) modality angle.
  • Knopp Biosciences: Clinical-stage small-molecule developer focused on ion channel and kinase targets for neuroscience indications including ALS. Comparable as a small-cap small-molecule neuroscience biotech.
  • Clene Nanomedicine: Clinical-stage biotech developing CNM-Au8, a gold nanocatalyst for ALS and other neurodegenerative diseases. Comparable emerging clinical-stage ALS therapeutics competitor.

Others

  • Ankarpharma SL: Earlier CSIC spin-off that held the CK-1δ patent transferred to Molefy Pharma at founding (2014). Direct lineage comparable as a Spanish neurodegenerative spin-off from the same research group.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Molefy pharma social profiles

Digital presence

Molefy pharma compliance and trust

Trust signal

Compliance1 record

Molefy pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molefy pharma leadership team

Management profile

Number of profiles

Profiles9 records

Molefy pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molefy pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molefy pharma

What does Molefy pharma do?

Molefy Pharma is a clinical-stage biotech company developing small-molecule therapeutics for neurodegenerative diseases. Its lead candidate AP-2, a CK1δ kinase inhibitor that restores TDP-43 protein homeostasis, is in Phase I clinical trials for Amyotrophic Lateral Sclerosis (ALS). Its second candidate AP-3, a TTBK1 inhibitor, is in preclinical development for frontotemporal dementia (FTD). Both are based on foundational patents licensed from CSIC and validated in patient-derived cellular and animal models.

Is Molefy pharma a public or private company?

Molefy pharma is a private company. It is classified as corporate owned and is currently operating.

When was Molefy pharma founded?

Molefy pharma was founded in 2024. It employs 1 to 10 people.

Where is Molefy pharma based?

Molefy pharma is headquartered in San Cristóbal De La Laguna, Spain, in the Europe region.

How does Molefy pharma make money?

Three revenue lines are on record. Pharmaceutical / Biopharmaceutical product revenues are the primary driver. The others are non-dilutive funding (grants) and equity investment rounds.

Who are Molefy pharma's main competitors?

Direct peers on record are Prothena, Cytokinetics and Amylyx Pharmaceuticals. Broad incumbents are Biogen and Ionis Pharmaceuticals. Emerging players are QurAlis Corporation, Knopp Biosciences and Clene Nanomedicine. Ankarpharma SL is listed as an others.

Does Molefy pharma have an API?

No public API is recorded for Molefy pharma.

What industry is Molefy pharma in?

Molefy pharma's product category is Biopharmaceuticals / Neurology Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales